Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroshi Hongo

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Cancer Science|September 27, 2024
Selective killing of castration-resistant prostate cancer cells by formycin A via the ATF4-CHOP axisTomoki Takei, Yuki Hamamura, Hiroshi Hongo, et al.
BMC Medical Genomics|June 20, 2022
A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case reportTomohiro Iwasawa, Takeo Kosaka, Shinya Morita, et al.
BMJ Open|November 25, 2021
Vasohibin-1 expression as a biomarker of aggressive nature in ductal adenocarcinoma of the prostate: a retrospective cohort study at two centres in JapanHiroaki Kobayashi, Takeo Kosaka, Shuji Mikami, et al.
IJU Case Reports|January 10, 2022
First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with <i>BRCA2</i> and <i>PTEN</i> alterationsMinami Omura, Takeo Kosaka, Eriko Aimono, et al.
Pathology International|October 22, 2019
A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutationTakeo Kosaka, Hiroshi Hongo, Eriko Aimono, et al.
Cardiovascular Intervention and Therapeutics|April 14, 2024
Importance of reassessment to identify trajectories of chronic transition of clinical indicators in post-myocardial infarction managementGoro Yoshioka, Atsushi Tanaka, Shinjo Sonoda, et al.
IJU Case Reports|July 14, 2021
Prominent response to platinum-based chemotherapy in a patient with <i>BRCA2</i> mutant-neuroendocrine prostate cancer and <i>MDM2</i> amplificationTatsuaki Daimon, Takeo Kosaka, Hiroshi Hongo, et al.
BMC Medical Genomics|October 10, 2021
A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterationsHiroaki Kobayashi, Takeo Kosaka, Kohei Nakamura, et al.
IJU Case Reports|May 12, 2021
First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletionKazunori Shojo, Takeo Kosaka, Kohei Nakamura, et al.
Nature Communications|June 19, 2021
Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancerKen-Ichi Takayama, Takeo Kosaka, Takashi Suzuki, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Cancer Science|September 27, 2024
Selective killing of castration-resistant prostate cancer cells by formycin A via the ATF4-CHOP axisTomoki Takei, Yuki Hamamura, Hiroshi Hongo, et al.
BMC Medical Genomics|June 20, 2022
A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case reportTomohiro Iwasawa, Takeo Kosaka, Shinya Morita, et al.
BMJ Open|November 25, 2021
Vasohibin-1 expression as a biomarker of aggressive nature in ductal adenocarcinoma of the prostate: a retrospective cohort study at two centres in JapanHiroaki Kobayashi, Takeo Kosaka, Shuji Mikami, et al.
IJU Case Reports|January 10, 2022
First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with <i>BRCA2</i> and <i>PTEN</i> alterationsMinami Omura, Takeo Kosaka, Eriko Aimono, et al.
Pathology International|October 22, 2019
A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutationTakeo Kosaka, Hiroshi Hongo, Eriko Aimono, et al.
Cardiovascular Intervention and Therapeutics|April 14, 2024
Importance of reassessment to identify trajectories of chronic transition of clinical indicators in post-myocardial infarction managementGoro Yoshioka, Atsushi Tanaka, Shinjo Sonoda, et al.
IJU Case Reports|July 14, 2021
Prominent response to platinum-based chemotherapy in a patient with <i>BRCA2</i> mutant-neuroendocrine prostate cancer and <i>MDM2</i> amplificationTatsuaki Daimon, Takeo Kosaka, Hiroshi Hongo, et al.
BMC Medical Genomics|October 10, 2021
A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterationsHiroaki Kobayashi, Takeo Kosaka, Kohei Nakamura, et al.
IJU Case Reports|May 12, 2021
First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletionKazunori Shojo, Takeo Kosaka, Kohei Nakamura, et al.
Nature Communications|June 19, 2021
Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancerKen-Ichi Takayama, Takeo Kosaka, Takashi Suzuki, et al.
Pageof 7